Prior research suggests that warfarin, when given concomitantly with some sulfonylureas, may increase the risk of serious hypoglycemia. however, the clinical significance remains unclear. We examined rate ratios (rrs) for the association between serious hypoglycemia and concomitant use of warfarin with either sulfonylureas or metformin using a self-controlled case series design and us medicaid claims (supplemented with medicare claims) from 1999 to 2011. across all risk windows combined, warfarin was associated with an elevated rate of serious hypoglycemia when given concomitantly with glimepiride (rr, 1.47; 95% confidence interval (Ci), 1.07-2.02) and metformin (rr, 1.73; 95% Ci, 1.38-2.16). Particularly in the late risk window (>120 days since beginning concomitancy), most of the rrs for warfarin were elevated: glipizide (rr, 1.72; 95% Ci, 1.29-2.29), glyburide (rr, 1.57; 95% Ci, 1.15-2.15), metformin (rr, 2.26; 95% Ci, 1.67-3.05), and glimepiride (rr, 1.56; 95% Ci, 0.97-2.50). These results are consistent with a previously hypothesized hypoglycemic effect of warfarin in patients with type 2 diabetes through inhibition of the carboxylation of osteocalcin.
The US National Action Plan for Adverse Drug Event Prevention 1 focuses on three common, clinically significant, and preventable adverse drug events: hypoglycemia from diabetes agents; bleeding from anticoagulants; and overdoses, oversedation, and respiratory depression from opioids. Among other measures, the plan calls for research on drug-drug interactions that may lead to these adverse events. Sulfonylureas and warfarin are among the drugs that are most frequently associated with adverse drug events. [1] [2] [3] [4] [5] [6] Han and colleagues conducted a series of high-throughput screening studies to identify potential drug-drug interactions involving sulfonylureas that may lead to serious hypoglycemia. 7 That article suggested that warfarin may be associated with an increased risk of serious hypoglycemia among persons taking glimepiride or glipizide. Furthermore, because cytochrome P450 (CYP) 2C9 is involved in the metabolism of both sulfonylureas [8] [9] [10] [11] [12] [13] and warfarin, [13] [14] [15] there is a potential pharmacokinetic mechanism for such an interaction. However, clinical significance of the potential interactions between these drugs remains unclear.
We studied whether warfarin is associated with an elevated rate of serious hypoglycemia when used concomitantly with
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
 Warfarin, when given concomitantly with some sulfonylureas, may increase the risk of serious hypoglycemia. However, the clinical importance of this potential effect is unclear.
WHAT QUESTION DID THIS STUDY ADDRESS?
 This study investigated whether warfarin use in combination with either sulfonylureas or metformin increases the risk of serious hypoglycemia.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
 This study found that warfarin was associated with an increased risk of serious hypoglycemia when used concomitantly with either a commonly used sulfonylurea (glimepiride, glipizide, or glyburide) or metformin, and that the increase in the risk was especially pronounced after prolonged concomitant therapy.
HOW MIGHT THIS CHANGE CLINICAL PHARMA COLOGY OR TRANSLATIONAL SCIENCE?
 The results are consistent with a previously hypothesized hypoglycemic effect of warfarin in patients with type 2 diabetes, which might be explained by warfarin's inhibition of the carboxylation of osteocalcin and a positive feedback loop. Physicians and patients will need to be vigilant about the potential increase in the risk of serious hypoglycemia associated with the use of warfarin during sulfonylurea or metformin therapy, especially with prolonged concomitant therapy. sulfonylureas using real-world large population data. In a drugdrug interaction, the object drug is the drug whose pharmacokinetics or pharmacodynamics is affected; the precipitant drug is the drug that affects the pharmacokinetics or pharmacodynamics of the object drug. 16 We measured the association between warfarin (the precipitant drug) and serious hypoglycemia in users of the most commonly used sulfonylureas (glimepiride, glipizide, and glyburide) as object drugs. Because we knew of no well-described mechanism by which warfarin could interact with metformin to increase the risk of hypoglycemia, we also included metformin as a negative control object drug, which is a drug that is used for similar indications as the object drugs under study, but is not believed to interact pharmacologically with the precipitant drugs. 16 
RESULTS
We identified 495, 1,123, 1,049, and 800 individuals who experienced serious hypoglycemia at least once while receiving glimepiride, glipizide, glyburide, or metformin, respectively. Table 1 shows the characteristics of these individuals by object drug. Table 2 and Figure 1 present rate ratios (RRs; with 95% confidence intervals (CIs)), defined as the rate of serious hypoglycemia during the concomitant use of the antidiabetes object drug with warfarin divided by the rate during the use of the antidiabetes object drug without warfarin. Across all risk windows combined, warfarin was associated with a statistically elevated rate of serious ACE, angiotensin-converting enzyme; CYP, cytochrome P450 enzyme; MAO, monoamine oxidase; Q, quartile. a Warfarin-triggered group: observation time (person-days) in which the concomitant use of object and precipitant drugs was initiated by warfarin during the ongoing antidiabetic treatment. b Antidiabetes-triggered group: observation time (person-days) in which the concomitant use of object and precipitant drugs was initiated by an antidiabetic drug during the ongoing warfarin treatment. c Combination-triggered group: observation time (person-days) in which the concomitant use of object and precipitant drugs was initiated by warfarin and an antidiabetic drug on the same day (i.e., prescriptions of warfarin and an antidiabetic drug were dispensed on the same day). d Small numbers of observation are suppressed by the cell suppression policy of the Centers for Medicare and Medicaid Services (data source). (Table S1) ; stratifying on concomitancy-triggering drug (Table S2) ; excluding individuals who had death outcome during the observation time (Table S3) ; and excluding individuals with potentially incomplete data ( Table S4) ) were substantively similar.
DISCUSSION
We found that the RR for the association between warfarin and serious hypoglycemia across all temporal risk windows combined was statistically elevated in users of glimepiride and in users of metformin, and nearly so in users of glipizide. In a prior study, warfarin use was associated with an elevated risk of serious hypoglycemia in users of either glipizide or glimepiride (odds ratio for both sulfonylureas considered collectively, 1.22; 95% CI, 1.05-1.42) and a similar, nearly statistically significantly elevated odds ratio in users of metformin. 17 In the present study, the association between warfarin and serious hypoglycemia appeared to be strongest after 120 days of concomitant use of warfarin with most of the antidiabetes drugs examined, including metformin. Given the lack of known pharmacokinetic or pharmacodynamic mechanisms by which warfarin could interact with metformin (which itself is associated with a low risk of hypoglycemia 18 ) to increase the risk of hypoglycemia, what could explain these findings?
Osteocalcin is a 49-amino acid protein that is produced by osteoblasts during bone formation. Its uncarboxylated form stimulates the secretion of insulin both through a direct effect on pancreatic islet cells and indirectly by stimulating the secretion of glucagon-like peptide-1 from the small intestine. 19 In addition to stimulating insulin secretion through these mechanisms, uncarboxylated osteocalcin also increases insulin sensitivity, 20 the combined effect of which would be expected to reduce blood glucose. The conversion of osteocalcin to its carboxylated form, which lacks effects on glucose metabolism, is vitamin K dependent and inhibited by warfarin. 21 Thus, there is a previously postulated mechanism for warfarin to lower blood glucose. Although warfarin's effects on blood glucose have not been studied in human trials, 19 in diabetic rats, it increases insulin secretion and reduces fasting glucose. 22 Moreover, a positive feedback loop has been postulated in which uncarboxylated osteocalcin stimulates insulin secretion, which further stimulates osteoblasts to produce uncarboxylated osteocalcin, the metabolism of which is inhibited by warfarin. 19 Such a positive feedback loop would be expected to result in a more marked hypoglycemic effect of warfarin after prolonged exposure, as is seen in Figure 1 . The increased rate of serious hypoglycemia with warfarin observed in users of metformin (which we had originally included as a negative control object drug) supports a previously hypothesized hypoglycemic effect of warfarin. It also suggests that the increased risk might be attributable primarily to a hypoglycemic effect of warfarin itself, rather than to a drug interaction between warfarin and either sulfonylureas or metformin, considering that the magnitude of the elevated risk was similar between sulfonylureas and metformin in both the current study and the earlier study. 17 Further research is needed to better understand underlying mechanisms.
This study has important strengths. It used a large healthcare database, which allowed examination of antidiabetes drugs individually rather grouping them and examination of associations over different risk windows of concomitancy. The study used an established well-performing algorithm to identify serious hypoglycemia. 23, 24 The self-controlled case series research design inherently avoids confounding by time-invariant patient factors and permits control for potential time-varying confounders, including apparent dose of the antidiabetes drug. Furthermore, we conducted several sensitivity analyses that suggest that our results are robust. This study also has limitations. First, it used administrative claims data, which lack information on actual ingestion of prescribed drugs, nonmedical or nonprescription drug therapy, dietary habits, and other health behaviors. However, such factors could have influenced the observed associations only if and to the degree that they varied within person and were temporally associated with warfarin use within individual. Furthermore, the magnitude of association seen in Medicaid enrollees, who tend to be vulnerable, may not reflect the magnitude in other populations. Therefore, further research in other populations is warranted. However, there would be no reason to believe that the relationships should be dramatically different in commercially insured populations. 25 In conclusion, we found that warfarin was associated with an elevated rate of serious hypoglycemia when used concomitantly with either a sulfonylurea or metformin, and that this elevation was especially pronounced after prolonged concomitant therapy. These results are consistent with a previously hypothesized hypoglycemic effect of warfarin in persons with type 2 diabetes, which might be explained by warfarin's inhibition of the carboxylation of osteocalcin and a positive feedback loop. Our findings suggest that physicians and patients need to be vigilant about the potential elevated risk of serious hypoglycemia associated with the use of warfarin during sulfonylurea or metformin therapy, especially with prolonged concomitant therapy.
METHODS

Overview of study design and data
We examined the RRs for serious hypoglycemia associated with warfarin as the precipitant drug among users of widely used sulfonylureas (glimepiride, glipizide, and glyburide (which account for >99% of all sulfonylureas in our data)) as object drugs and in users of metformin as a negative control object drug. The use of a negative control object drug helps to distinguish a drug-drug interaction from the inherent effect of the precipitant drug itself and to avoid confounding by indication. 16 We used the self-controlled case series research design, [26] [27] [28] which includes only persons who experienced the outcome of interest within the observation time (in this case, time exposed to a sulfonylurea or metformin), using each person as his or her own control. This design inherently eliminates confounding by factors that do not change within individual over the observation period. 29 We also conducted sensitivity analyses to examine the robustness of our primary results by (i) controlling for average daily dose of antidiabetes drugs; (ii) performing the analysis by concomitancy-triggering drug (i.e., warfarin-triggered, antidiabetestriggered, and combination-triggered group) 16 ; (iii) excluding individuals who had death outcome during the observation time; and (iv) excluding individuals with potentially incomplete data (operational definition: individuals with a managed care plan, private health insurance, restricted benefits, or among Medicaid-Medicare dual enrollees, or individuals enrolled in a group health organization or a Medicare Advantage plan for which the Centers for Medicare and Medicaid Services does not process provider claims).
We used data from five US Medicaid programs (California, Florida, New York, Ohio, and Pennsylvania) from 1999 to 2011, 25 We linked these data to the Social Security Administration Death Master File to ascertain deaths. Adults (18 ≤ age < 100 years) who had continuous enrollment in Medicaid for at least 6 months before the first observation time were included.
Exposure of interest and covariates
The exposure of interest was the concomitant use of warfarin with either a sulfonylurea or metformin during the observation time (described below). Because the self-controlled case series design inherently controls for static patient factors, we adjusted only for the time-varying covariates listed in Table 3 , including the following: (i) drug that may cause hypoglycemia (e.g., angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, β blockers, quinolones, and monoamine oxidase inhibitors); (ii) drugs that may cause hyperglycemia (e.g., thiazide and thiazidelike diuretics, corticosteroids, protease inhibitors, retinoid, atypical antipsychotics, and calcineurin inhibitors); (iii) drugs that interact with sulfonylureas (e.g., CYP2C9 inhibitors and CYP3A4 inhibitors); (iv) major acute condition that may affect hypoglycemia (e.g., acute infection); and (v) additionally in the sensitivity analysis, average daily dose of object antidiabetes drugs as a continuous variable, which was defined as the multiplication of the quantity and strength of the prescribed drug divided by the days' supply of the prescribed drug. In this sensitivity analysis, we excluded as potentially implausible average daily doses greater than two times maximum daily dose of each object drug: glimepiride, 16 mg/day; glipizide, 80 mg/day; glyburide, 40 mg/day; and metformin, 5,100 mg/day. Figure 1 Primary analysis: confounder-adjusted outcome occurrence rate ratios and 95% confidence intervals for the association between warfarin and serious hypoglycemia when used with a sulfonylurea or metformin.
Outcome of interest
The outcome of interest was serious hypoglycemia, and ascertained by the following International Classification of Diseases, Ninth Revision, Clinical Modification discharge diagnosis codes appearing in the principal position of an inpatient claim or in any position of an emergency department claim: 251.0 (hypoglycemic coma); 251.1 (other specific hypoglycemia); 251.2 (hypoglycemia, unspecified); or 280.8X (diabetes with other specified manifestations), unless accompanied by one of the exclusionary diagnosis codes suggesting manifestations other than hypoglycemia (presented in Table 4 ). This algorithm has a positive predictive value of 89% 23 in emergency department claims and 78% 24 in inpatient claims.
Study cohorts
We constructed our study cohorts for each object drug (glimepiride, glipizide, glyburide, or metformin) separately. We constructed an object drug's episodes by using dispensing date and days' supply fields from prescription claims. An episode was defined as a unit of continuous prescriptions that only allowed a grace period to allow for potential incomplete adherence, a 14-day gap in our study, between contiguous prescriptions and at the end of the last prescription. Warfarin episodes were constructed by the same method. The object drug episodes served as the basis of observation time, and individuals were allowed to contribute more than one episode and more than one outcome occurrence within an episode included in the analysis if inclusion/ exclusion and baseline period criteria were met. We included only observation episodes during which the outcome of interest occurred at least once (i.e., once or more; not restricted to incident events), regardless of whether it occurred during a period of warfarin exposure or nonexposure.
Observation time and baseline periods Observation time was composed of object antidiabetes drug episodes in which at least one outcome event occurred. An object drug's episode began at the first dispensing date of that episode and ended by the first occurrence of the following: (i) end of days' supply of the episode, including a 14-day grace period; (ii) Medicaid enrollment discontinuation; (iii) death; and (iv) end of data set (i.e., December 31, 2011). The occurrence of the outcome of interest (i.e., serious hypoglycemia) did not end the object drug's episode on the basis of the independent exposure assumption of the self-controlled case series design to avoid bias from reverse causality. Because death is a reason that permanently ends the observation time, we also performed a sensitivity analysis (described below) that only included individuals alive throughout the observation time. Person-days with concomitant use of object and precipitant drugs were categorized into four prespecified risk windows by the number of days since the initiation of concomitant use: (i) 0-30 days, (ii) 31-60 days, (iii) 61-120 days, and (iv) >120 days.
To reduce potential bias in estimation from the uncertain incomplete capture of data (e.g., unseen prescriptions during the Medicaid disenrollment period that do not enable us to identify the correct start date of an object drug episode and/or the concomitant use of a precipitant drug from the Medicaid claims data), we applied a 6-month baseline period criterion immediately before the first object drug's episode, which was devoid of the following: (i) Medicaid enrollment gap; (ii) death; and (iii) a prescription claim for the object drug. In case an individual disenrolled from Medicaid after contributing to an observation time and reenrolled in Medicaid later, we applied again the baseline period criterion immediately before the first object drug episode identified since the reenrollment and the requirement of at least one outcome occurrence during the observation time.
Statistical analysis
We performed a conditional Poisson regression analysis, 9 estimating occurrence RRs (i.e., outcome occurrence rate during exposed time vs. unexposed time; exposed time refers to time of concomitant use of the antidiabetes drug with warfarin, and unexposed time refers to time of use of the antidiabetes drug without warfarin) and 95% CIs. The dependent variable was an indicator variable for the outcome occurrence. Independent variables were as follows: indicator of concomitant use (i.e., exposure to warfarin) status; and the prespecified time-varying covariates presented in Table 1 and Table 3 . The unit of analysis was a person-day of observation time. For each antidiabetes drug, we examined the RR for warfarin across all risk windows combined and within the prespecified risk windows previously listed.
All analyses were conducted using SAS, version 9.4 (SAS Institute, Cary, NC). This study was approved by the institutional review board of the University of Pennsylvania (Philadelphia, PA), which waived the obtainment of informed consent.
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